Despite the initial indications of FIIN-2’s effectiveness in impeding BAG2-CHIP-mediated gastric cancer proliferation in both in vitro and in vivo models, it is acknowledged that the present study is not without its limitations. This evidence concerns the gene BAG2 and gastric cancer.